Quince Therapeutics (QNCX) Net Cash Flow (2018 - 2026)

Quince Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at $98.0 million in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 985.07% year-over-year to $98.0 million in Q2 2026; TTM through Jun 2026 was $101.2 million, a 1078.95% increase from a year earlier, with the FY2025 full-year figure at -$289000.0, up 98.04% from the prior year.
• Net Cash Flow was $98.0 million for Q2 2026 at Quince Therapeutics, up from $13.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $98.0 million in Q2 2026, with the low at -$24.1 million in Q2 2023.
• Average Net Cash Flow over 5 years is $2.6 million, with a median of -$503500.0 recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Net Cash Flow slumped 339.47% in 2024, then soared 985.07% in 2026.
• Over 5 years, Net Cash Flow stood at $12.8 million in 2022, then slumped by 104.92% to -$631000.0 in 2023, then soared by 625.36% to $3.3 million in 2024, then plunged by 111.34% to -$376000.0 in 2025, then jumped by 26176.33% to $98.0 million in 2026.
• The last three Net Cash Flow figures came in at $98.0 million (Q2 2026), $13.8 million (Q1 2026), and -$376000.0 (Q4 2025), per Business Quant data.